The history of the tetracyclines

The history of the tetracyclines involves the collective contributions of thousands of dedicated researchers, scientists, clinicians, and business executives over the course of more than 60 years. Discovered as natural products from actinomycetes soil bacteria, the tetracyclines were first reported...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Annals of the New York Academy of Sciences Ročník 1241; číslo 1; s. 17 - 32
Hlavní autoři:	Nelson, Mark L., Levy, Stuart B.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Malden, USA Blackwell Publishing Inc 01.12.2011 Wiley Subscription Services, Inc
Témata:	Bacteria Bacterial Infections - drug therapy Bacterial Infections - history bioactivity Biological Business Chemical properties Chlortetracycline - history Chlortetracycline - isolation & purification Chlortetracycline - therapeutic use Derivatives Diseases Drug Discovery - history history History, 20th Century History, 21st Century History, Ancient Humans Infectious diseases Mammals mechanism Microorganisms Oxytetracycline - history Oxytetracycline - isolation & purification Oxytetracycline - therapeutic use Pharmacokinetics resistance Soil Microbiology Streptomyces aureofaciens - chemistry Tetracycline Resistance Tetracyclines Tetracyclines - history Tetracyclines - isolation & purification Tetracyclines - therapeutic use uses
ISSN:	0077-8923, 1749-6632, 1749-6632
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	The history of the tetracyclines involves the collective contributions of thousands of dedicated researchers, scientists, clinicians, and business executives over the course of more than 60 years. Discovered as natural products from actinomycetes soil bacteria, the tetracyclines were first reported in the scientific literature in 1948. They were noted for their broad spectrum antibacterial activity and were commercialized with clinical success beginning in the late 1940s to the early 1950s. The second‐generation semisynthetic analogs and more recent third‐generation compounds show the continued evolution of the tetracycline scaffold toward derivatives with increased potency as well as efficacy against tetracycline‐resistant bacteria, with improved pharmacokinetic and chemical properties. Their biologic activity against a wide spectrum of microbial pathogens and their uses in mammalian models of inflammation, neurodegeneration, and other biological systems indicate that the tetracyclines will continue to be successful therapeutics in infectious diseases and as potential therapeutics against inflammation‐based mammalian cell diseases.
Bibliografie:	ark:/67375/WNG-L5FBCH6F-2 istex:7E918F5D7B1C02E12692809C030DDD859DA998FC ArticleID:NYAS6354 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Review-3
ISSN:	0077-8923 1749-6632 1749-6632
DOI:	10.1111/j.1749-6632.2011.06354.x